

## **SIgN affiliated publications by NEO Shi Yong**

*Last updated: 23 April 2026*

### **2026**

Cruz De Los Santos M, Chen Y, González De Zárate A, Sorteberg A, Zhao H, Vázquez-Cabrera G, Bigdeli N, Kolbeinsdóttir S, Mannion A, Baldran-Groves L, Neo SY, Wickström SL, Melief J, Holmgren L, Herold N, Haglund de Flon F, Lundqvist A. Epigenetic remodeling in sarcoma promotes T-cell infiltration via modulation of the Hippo pathway. *J Immunother Cancer*. 2026;14(4):e014601.

### **2025**

Lee K, Kim S, Zhao J, Neo SY. Targeting archetypes of viral-driven cancers with immunotherapy: a perspective on immunogenicity within the tumor microenvironment. *Front Immunol*. 2025 Aug 29;16:1631258.

Tong L, Tay AHM, Cui W, Liu Y, Su Y, Lyu J, Hoedemakers L, Yang Y, Ehnman M, Seliger B, Nordlund P, Haglund de Flon F, Neo SY, Lundqvist A. VHL restoration in clear cell renal cell carcinoma improves NK cell infiltration and function. *Cancer Immunol Immunother*. 2025 Jul 30;74(9):278.

Sun Y, Rodgers Furones A, Gultekin O, Khare S, Neo SY, Shi W, Moyano-Galceran L, Lam KP, Dasgupta R, Fuxe J, Salehi S, Lehti K, Sarhan D. Adaptive NK Cells Exhibit Tumor-Specific Immune Memory and Cytotoxicity in Ovarian Cancer. *Cancer Immunol Res*. 2025 Jul 2;13(7):1080-1097.

Tong L, Kremer V, Neo SY, Seitz C, Tobin NP, Seliger B, Harmenberg U, Colón E, Scherman Plogell AH, Liu LL, Lundqvist, A. Cellular and secretome profiling uncover immunological biomarkers in the prognosis of renal cell carcinoma patients. *Oncoimmunology*. 2025;14(1):2481109.

Neo SY, Shuen TWH, Khare S, Chong J, Lau M, Shirgaonkar N, Chua L, Zhao J, Lee K, Tan C, Ba R, Lim J, Chua J, Cheong HS, Chai HM, Chan CY, Chung AYF, Cheow PC, Jeyaraj PR, Teo JY, Koh YX, Chok AY, Chow PKH, Goh B, Wan WK, Leow WQ, Loh TJZ, Tang PY, Karunanithi J, Ngo NT, Lim TKH, Xu S, Dasgupta R, Toh HC, Lam, KP. Atypical memory B cells acquire Breg phenotypes in hepatocellular carcinoma. *JCI Insight*. 2025.

### **2024**

Lv R, Guo Y, Liu W, Dong G, Liu X, Li C, Ren Y, Zhang Z, Neo SY, Mao W, Wu J. Revolutionizing cancer treatment: the emerging potential and potential challenges of in vivo self-processed CAR cell therapy. *Theranostics*. 2024;14(19):7424-7447.

Neo SY, Tong L, Chong J, Liu Y, Jing X, Oliveira MMS, Chen Y, Chen Z, Lee K, Burduli N, Chen X, Gao J, Ma R, Lim JP, Huo J, Xu S, Alici E, Wickström SL, Haglund F, Hartman J, Wagner AK, Cao Y, Kiessling R, Lam KP, Westerberg LS, Lundqvist A. Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis. *Sci Transl Med*. 2024 May 15;16(747).

Neo SY, Oliveira MMS, Tong L, Chen Y, Chen Z, Cismas S, Burduli N, Malmerfelt A, Teo JKH, Lam KP, Alici E, Girnita L, Wagner AK, Westerberg LS, Lundqvist A. Natural killer cells drive 4-1BBL positive uveal melanoma towards EMT and metastatic disease. *J Exp Clin Cancer Res*. 2024;43(1):13.

## 2023

Tong L, Kremer V, [Neo SY](#), Liu Y, Chen Y, Wagner AK, Yang Y, Chen Z, Seitz C, Tobin NP, Ligtenberg MA, Alici E, Chen X, Haglund F, Seliger B, Harmenberg U, Colón E, Plogell AS, Liu LL, Lundqvist A. Renal cell carcinoma escapes NK cell-mediated immune surveillance through the downregulation of DNAM-1. *Cancer Commun (Lond)*. 2023.

[Neo SY#](#), [Xu S](#), [Chong J](#), [Lam KP](#), Wu J. Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer. *J Immunother Cancer*. 2023;11(4).

Zhao J, [Lee K](#), Toh HC, [Lam KP](#), [Neo SY#](#). Unravelling the role of obesity and lipids during tumor progression. *Front Pharmacol*. 2023; 14:1163160.

[Strickland M](#), [Lee S](#), [Neo SY](#), [Balachander A](#), [Low I](#), [Mustafah S](#), [Goh WI](#), [Wright GD](#), [Larbi A](#), [Pender SLF](#). Mitochondrial Dysfunction in CD4+ T Effector Memory RA+ Cells. *Biology (Basel)*. 2023;12(4).

Chen Z, Tong L, [Neo SY](#), Li S, Gao J, Schlisio S, Lundqvist A. CD25(bright) NK cells display superior function and metabolic activity under regulatory T cell-mediated suppression. *Oncoimmunology*. 2023;12(1):2175517.

Cismas S, Pasca S, Crudden C, Trocoli Drakensjo I, Suleymanova N, Zhang S, Gebhard B, Song D, [Neo SY](#), Shibano T, Smith TJ, Calin GA, Girnita A, Girnita L. Competing Engagement of beta-arrestin Isoforms Balances IGF1R/p53 Signaling and Controls Melanoma Cell Chemotherapeutic Responsiveness. *Mol Cancer Res*. 2023;21(12):1288-1302.

Sun C, Wen K, Zhang B, Dong Y, Chen C, [Neo SY](#), Leng B, Gao TT, Wu J. DSC2 suppresses the growth of gastric cancer through the inhibition of nuclear translocation of gamma-catenin and PTEN/PI3K/AKT signaling pathway. *Aging (Albany NY)*. 2023;15(13):6380-6399.

## 2022

[Neo SY\\*](#), [Jing X\\*](#), Tong L, Tong D, Gao J, Chen Z, De Los Santos MC, Burduli N, De Souza Ferreira S, Wagner AK, Alici E, Rolny C, Cao Y, Lundqvist A. Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells. *J Immunother Cancer*. 2022;10(10).

Sun Q, Gao Y, Zhang Y, Cao H, Liu J, [Neo SY](#), Chen K, Bi Y, Wu J. Prognostic Profiling of the EMT-Associated and Immunity-Related lncRNAs in Lung Squamous Cell Carcinomas. *Cells*. 2022;11(18).

Tay AHM, Prieto-Diaz R, [Neo SY](#), Tong L, Chen X, Carannante V, Önfelt B, Hartman J, Haglund F, Majellaro M, Azuaje J, Garcia-Mera X, Brea JM, Loza MI, Jespers W, Gutierrez-de-Teran H, Sotelo E, Lundqvist A. A(2B) adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models. *J Immunother Cancer*. 2022;10(5).

Xing X, Mu N, Yuan X, Wang N, Juhlin CC, Straat K, Larsson C, [Neo SY](#), Xu D. Downregulation and Hypermethylation of GABPB1 Is Associated with Aggressive Thyroid Cancer Features. *Cancers (Basel)*. 2022;14(6).